Tirofiban Hydrochloride Hydrate

Tier C — Watch / trade

MSD (Merck Sharp & Dohme)

Originator

1998

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GP IIb/IIIa

Brand：Aggrastat

Indications (approved)：Unstable angina, Myocardial infarction, Coronary thrombosis, Acute coronary syndrome, Thrombosis

Regional status

Approved

1998-05-14

China

Approved

2003-06-13

Japan

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Tirofiban Hydrochloride Hydrate?

Approved indications include: Unstable angina, Myocardial infarction, Coronary thrombosis, Acute coronary syndrome, Thrombosis.

When does the Tirofiban Hydrochloride Hydrate patent expire?

No public expiry year is available for Tirofiban Hydrochloride Hydrate yet; this page updates once verified.

How do I get a quote for Tirofiban Hydrochloride Hydrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27